A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

  • End date
    Jun 16, 2023
  • participants needed
  • sponsor
    MedImmune LLC
Updated on 16 January 2021
AstraZeneca Clinical Study Information Center
Primary Contact
Research Site (7.8 mi away) Contact
+16 other location


The purpose of this study is to evaluate MEDI5752 in combination with axitinib.in subjects with advanced renal cell carcinoma.


The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI5752 in combination with axitinib in subjects with advanced renal cell carcinoma.

Treatment Axitinib, MEDI5752
Clinical Study IdentifierNCT04522323
SponsorMedImmune LLC
Last Modified on16 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 101 yrs?
Gender: Male or Female
Do you have Advanced Renal Cell Carcinoma?
Do you have any of these conditions: Do you have Advanced Renal Cell Carcinoma??
Do you have any of these conditions: Do you have Advanced Renal Cell Carcinoma??
Do you have any of these conditions: Do you have Advanced Renal Cell Carcinoma??
History of arrhythmia which is symptomatic or requires treatment symptomatic or uncontrolled atrial fibrillation despite treatment
Uncontrolled intercurrent illness within the last 6 months prior to enrollment
Clinically significant gastrointestinal abnormality
Evidence of inadequate wound healing
Current use or anticipated need for treatment with drugs or foods that are known strong CYP3A4/5 inhibitors

Exclusion Criteria

Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
Concurrent enrollment in another clinical study, unless it is an observational study
Previous treatment with mTOR inhibitors, PD-1, PD-L1, or CTLA-4 inhibitors for RCC or any other immune checkpoint inhibitors
Previous treatment with axitinib; other VEGF TKIs used in the adjuvant setting are allowed if last dose > 6 months prior to the first dose of investigational product
History of active primary immunodeficiency
History of organ transplant
Active or prior documented autoimmune or inflammatory disorders
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of investigational product
Has poorly controlled hypertension defined as systolic BP 140 mm Hg and/or diastolic BP 90 mm Hg
Thromboembolic (arterial or venous) events within previous 6 months
Any concurrent therapy for cancer
Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product
Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s)
Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression
History of another primary malignancy
Unresolved toxicities from previous anticancer therapy
Major surgery within 4 weeks prior to enrollment or radiation therapy within 2 weeks prior to enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet